Tutti gli studi
Attivo ma non reclutanteFASE3INTERVENTISTICO

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

This research study is testing a new medicine called Efgartigimod PH20 SC for adults who have ocular myasthenia gravis. This condition mainly causes weakness in the eye muscles, leading to problems like drooping eyelids or double vision. The main goals are to find out if this medicine is safe to use and if it can help improve these eye symptoms. The study is split into two parts. In the first part, some participants will receive the active medicine, while others will get a placebo (a dummy medicine with no active ingredients). This helps researchers see the true effect of the new medicine. In the second part, all participants will receive the active medicine. The study will last for about two years and 12 weeks in total.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE3
Sponsor
argenx
Obiettivo di iscrizione
141
Inizio
18 Sep 2024
Completamento stimato
01 Dic 2027

Di cosa tratta questo studio?

This study is about a new way to treat a condition called ocular myasthenia gravis. If you have this condition, your immune system mistakenly attacks healthy parts of your body, specifically the connections between your nerves and eye muscles. This can lead to symptoms like drooping eyelids or seeing double. The new medicine being tested, Efgartigimod PH20 SC, is given by an injection under the skin using a special pre-filled syringe.

The main aim of the study is to see how well this new medicine works and if it's safe for people with ocular myasthenia gravis. The researchers want to understand if it can help to reduce or improve the eye symptoms that people experience. Knowing if a new treatment is both effective and safe is very important before it can be widely used.

The study is designed in two stages. Initially, some people will get the new medicine, and others will get a placebo, which looks just like the study medicine but doesn’t contain any active ingredients. This comparison helps researchers determine if any improvements are truly due to the medicine. Later on, everyone in the study will have the chance to receive the active medicine. This long-term approach helps track how participants respond over time.

Punti chiave

  • This study tests a new injection for adults with eye muscle weakness from myasthenia gravis.
  • It aims to check if the medicine, Efgartigimod, is safe and helps improve eye symptoms.
  • The study involves a comparison with a dummy medicine (placebo) initially.
  • Participation lasts for about two years and 12 weeks.
  • All participants will receive the active medicine in the later part of the study.

Chi può essere idoneo?

To be able to join this study, you must be at least 18 years old.

You also need to have a clear diagnosis of myasthenia gravis, specifically the type that mostly affects the eyes (ocular myasthenia gravis). Doctors will confirm this diagnosis through specific tests, such as blood tests looking for certain antibodies or nerve tests. Your current eye symptoms, such as drooping eyelids or double vision, should also be at a certain level to be included.

There are also some reasons why you might not be able to join. For example, if you have other medical conditions that cause similar eye symptoms, or other serious health problems that might make it unsafe to take part or make it hard to tell if the study medicine is working, you would not be able to participate.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai almeno 18 anni?
  2. Do you have a confirmed diagnosis of myasthenia gravis that mainly affects your eyes?
  3. Are your current eye symptoms at a certain level, such as significant drooping eyelids or double vision?
  4. Do you have any other serious health problems that might complicate your participation?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you join this study, you'll be involved for about two years and 12 weeks. During this time, you will have regular visits to the study clinic. These visits will involve health checks, assessments of your eye symptoms, and possibly blood tests or other evaluations to see how you are responding to the treatment.

For the first part of the study (about 7 weeks), you will either receive the new medicine, Efgartigimod PH20 SC, or a placebo (a dummy medicine), given by an injection under the skin using a pre-filled syringe. Neither you nor your study doctor will know which one you are receiving during this phase. After this, everyone in the study will receive the active Efgartigimod medicine for the rest of the study period.

Rischi e benefici potenziali

Taking part in a study like this might have potential benefits if the new medicine helps to improve your ocular myasthenia gravis symptoms. However, as with all medicines, there could be risks of side effects, which the study team will monitor closely. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (102)

  • HonorHealth Neurology - Bob Bové Neuroscience Institute
    Codice postale verificato
    Scottsdale, Stati Uniti
  • Loma Linda University Health
    Codice postale verificato
    Loma Linda, United States
  • USC Roski Eye Institute - Los Angeles
    Codice postale verificato
    Los Angeles, Stati Uniti
  • University of California San Francisco
    Codice postale verificato
    San Francisco, Stati Uniti
  • Neurology Offices of South Florida
    Codice postale verificato
    Boca Raton, United States
  • SFM Clinical Research, LLC
    Codice postale verificato
    Boca Raton, United States
  • Neurology Associates PA
    Codice postale verificato
    Maitland, United States
  • University of South Florida
    Codice postale verificato
    Tampa, Stati Uniti
  • Northwestern Memorial Hospital
    Codice postale verificato
    Chicago, Stati Uniti
  • University of California Irvine
    Codice postale verificato
    Columbia, United States
  • Massachusetts General Hospital
    Codice postale verificato
    Boston, Stati Uniti
  • Henry Ford Health System
    Codice postale verificato
    Detroit, Stati Uniti

Domande comuni

What is ocular myasthenia gravis?

It's a condition where your body's immune system attacks your eye muscles, causing weakness, drooping eyelids, or double vision.

Che cos'è un placebo?

A placebo is a 'dummy' medicine that looks like the real treatment but contains no active ingredients. It helps researchers compare the true effects of the new medicine.

Quanto durerà lo studio se partecipo?

The study will last for about two years and 12 weeks in total.

Sapró se sto ricevendo il vero medicinale o il placebo?

In the first part of the study, neither you nor your study doctor will know. This is a common way to test new medicines fairly.

What does 'Efgartigimod PH20 SC' mean?

Efgartigimod is the name of the new medicine being tested, and 'SC' means it's given by a 'subcutaneous' injection, which is under the skin.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.